📰 Repligen Corp News
Page 6 - Repligen Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Repligen Corp. Real-time updates on events, politics, business and more.
May 3, 2023
Repligen (NASDAQ:RGEN – Get Rating) had its price objective dropped by research analysts at Royal Bank of Canada from $170.00 to $157.00 in a note issued to investors on Wednesday, The Fly reports. Royal Bank of Canada’s price target would suggest a potential downside of 3.20% from the stock’s previous close. A number of other […]
May 3, 2023
Repligen (NASDAQ:RGEN – Get Rating) had its price objective cut by Royal Bank of Canada from $170.00 to $157.00 in a research report issued on Wednesday, The Fly reports. Royal Bank of Canada’s target price indicates a potential downside of 3.20% from the company’s previous close. Several other research firms have also recently commented on […]
May 3, 2023
Repligen (NASDAQ:RGEN – Get Rating) had its price objective cut by research analysts at Benchmark from $230.00 to $210.00 in a research report issued on Wednesday, The Fly reports. Benchmark’s target price points to a potential upside of 33.56% from the stock’s previous close. A number of other equities research analysts also recently weighed in […]
May 3, 2023
Repligen (NASDAQ:RGEN – Get Rating) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05, Briefing.com reports. The firm had revenue of $182.70 million for the quarter, compared to analyst estimates of $181.43 million. Repligen had a return on […]
May 3, 2023
Should You Buy or Sell Repligen Stock? Get The Latest RGEN Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
May 2, 2023
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Repligen Corp. (RGEN) on Tuesday reported...
May 2, 2023
Repligen (NASDAQ:RGEN – Get Rating) updated its FY23 earnings guidance on Tuesday. The company provided EPS guidance of $2.35-$2.42 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. Wall Street Analyst Weigh In A number of […]
May 2, 2023
Geneva Capital Management LLC reduced its position in Repligen Co. (NASDAQ:RGEN – Get Rating) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,065 shares of the biotechnology company’s stock after selling 12,348 shares during the quarter. Geneva […]
May 2, 2023
Repligen Corp RGEN reported Q1 FY23 sales of $182.66 million, down 12% Y/Y as reported, beating the consensus of $181.43 million. • Adjusted EPS fell 30.4% to…
May 1, 2023
Repligen (NASDAQ:RGEN – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 2nd. Analysts expect Repligen to post earnings of $0.59 per share for the quarter. Repligen has set its FY23 guidance at $2.61-2.69 EPS and its FY 2023 guidance at $2.61-$2.69 EPS.Persons that are interested in […]